Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel. The TRPML1 variant that lacks the endo-lysosomal retention sequences (TRPML1-4A) is used, enabling the channel to express at the plasma membrane. As such, channel behaviour can be successfully characterised by:
Read our case study: Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms
Contact Metrion to advance your preclinical drug discovery project
We developed a high-throughput, electrophysiological assay of TREK-1 function to identify novel modulators. The assay was optimized to identify both activators and inhibitors, providing comprehensive mechanistic data for high value, limited supply screening libraries, such as the venom fraction library used in this study (Targeted Venom Discovery Array, T-VDA, Venomtech, UK).
We developed a high-throughput, electrophysiological assay of TREK-1 function to identify novel modulators. The assay was optimized to identify both activators and inhibitors, providing comprehensive mechanistic data for high value, limited supply screening libraries, such as the venom fraction library used in this study (Targeted Venom Discovery Array, T-VDA, Venomtech, UK).